Thus, as shown in Figure 4, to accurately validate circulating levels of IL-37 as a diagnostic tool in T2D patients, there is the need to recognize several MS phenotypes, relating them to the degree of frailty, sarcopenia, and categories of BMI. This evidence concerns the gene IL37 and myeloid sarcoma.